Spruce Biosciences, Inc. (SPRB)
Healthcare · NCM
Fundamentals
Valuation and ratings
Spruce Biosciences, Inc. trades at USD43.08, which is 41% above the USD25.25 our discounted cash flow model puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 10 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
SPRB earnings and analyst estimates
Recommendation mix, 8 analyst ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Spruce Biosciences, Inc.
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
SPRB passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Common questions
Is Spruce Biosciences, Inc. (SPRB) undervalued?
Against our discounted cash flow estimate of USD25.25, SPRB at USD43.08 is 41% above fair value. That is one model's answer, not a recommendation, and most of a DCF's output sits in a terminal value nobody can forecast.
The full research page for SPRB, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.